Home > Boards > US Listed > Electronics and components > Agilent Technologies Inc. (A)

Sometimes it is not what is said that

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
sblfe Member Profile
 
Followed By 0
Posts 13
Boards Moderated 0
Alias Born 05/05/16
160x600 placeholder
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC) Business Wire - 6/11/2019 7:56:00 AM
Agilent Technologies Announces Webcasts for Investment Community Business Wire - 6/4/2019 11:00:00 AM
Agilent Survey of Pharma Lab Leaders Uncovers Challenges in Workflow and Laboratory Efficiencies Business Wire - 6/4/2019 8:00:00 AM
Agilent Introduces Intelligent LC/MS System for Chromatographers at ASMS 2019 Business Wire - 6/3/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/30/2019 4:11:02 PM
Agilent Showcases Mass Spec Solutions at ASMS 2019 Business Wire - 5/30/2019 8:00:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/23/2019 4:07:26 PM
Agilent Technologies Announces Cash Dividend of 16.4 Cents per Share Business Wire - 5/22/2019 4:05:00 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 5/21/2019 4:18:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2019 7:34:26 PM
Agilent Technologies Shares Fall After Slower Sales From China Dow Jones News - 5/15/2019 12:01:00 PM
Agilent Technologies Down Nearly 10%, on Pace for Largest Percent Decrease Since August 2011 -- Data Talk Dow Jones News - 5/15/2019 11:49:00 AM
Agilent 2Q Profit Falls, Misses Revenue Expectations Dow Jones News - 5/14/2019 4:53:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 4:11:51 PM
Agilent Technologies Reports Second Quarter Fiscal Year 2019 Financial Results Business Wire - 5/14/2019 4:05:00 PM
Agilent Announces Unique Portfolio to Advance Immunotherapy Business Wire - 5/7/2019 8:00:00 AM
Agilent and SomaLogic Sign Agreement for Supply of Custom Microarrays Business Wire - 4/30/2019 8:00:00 AM
Agilent Receives an Expanded FDA Approval for its Companion Diagnostic in NSCLC Business Wire - 4/16/2019 8:04:00 PM
ACEA Biosciences – A Part of Agilent Launches the xCELLigence RTCA ePacer to improve the Quality & Functionality of hiPSC-C... Business Wire - 4/16/2019 8:00:00 AM
Agilent Technologies to Host Webcast of Second-Quarter Fiscal Year 2019 Financial Results Conference Call Business Wire - 4/16/2019 7:00:00 AM
Agilent Introduces New Mass Spectrometry Solutions Business Wire - 4/15/2019 8:25:00 AM
Agilent Presents Thought Leader Award to Professor Antoni Ribas Business Wire - 4/12/2019 11:00:00 AM
Agilent Introduces New System for RNA and DNA Quality Control Laboratories Business Wire - 4/2/2019 11:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/28/2019 1:46:05 PM
Agilent to Host National Academy of Engineering Business Meeting and Bioengineering Symposium Business Wire - 3/28/2019 11:00:00 AM
sblfe   Wednesday, 09/12/18 01:29:38 PM
Re: None
Post # of 56 
Sometimes it is not what is said that is important but rather what is not said..

Today's press release:

This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention. The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study. As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018. The AHA has not been provided any advanced access to the results of this study.

Notice they stated that the AHA has NOT yet seen the results of the study. Notice that it did not state that Amarin hasn't seen it like JT has said in the past. To push to present at the AHA w/ knowledge of the result is a positive as they would not be in a hurry if it was negative. Also, you can not provide advanced access to the results if you don't have it. You'd simply say we still do not have the results.

Essentially we know they have the results. The question is whether they completely understand it and that is the sole reason why it has not been PR'ed yet. I could be reading into something that isn't there or wasn't intentional but the way its written subtly implies they have it and by PR'ing their push to present it asap, reflects what is likely a positive outcome.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist